{"id":97934,"date":"2024-01-18T05:21:29","date_gmt":"2024-01-18T05:21:29","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=116009"},"modified":"2024-01-18T05:21:29","modified_gmt":"2024-01-18T05:21:29","slug":"nyxoah-announces-2024-strategic-priorities","status":"publish","type":"post","link":"https:\/\/jordannewsgazette.com\/nyxoah-announces-2024-strategic-priorities\/","title":{"rendered":"Nyxoah Announces 2024 Strategic Priorities"},"content":{"rendered":"
\n

Nyxoah Announces 2024 Strategic Priorities<\/strong><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 January 17, 2024, 10:05pm CET \/ 4:05pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024.<\/p>\n

2024 Strategic Priorities<\/strong><\/p>\n